Epigenetic pharmacology

Richard Burkhart, Anup R. Sharma, Nita Ahuja

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Decades of research focused on the genetic basis for development of pancreatic ductal adenocarcinoma have yielded tremendous discoveries. Clues to increase our understanding of the underlying biology of disease, the time along which the disease develops, and the potential vulnerabilities of disease are being elucidated daily. Alongside this genetically driven paradigm, researchers have uncovered the phenomenon of dramatically altered protein expression in the absence of an associated gene mutation. Through a mechanism termed epigenetics, the transcription and translation of genes can be dramatically altered by a variety of mechanisms including DNA methylation and histone modification. The fundamental concepts of epigenetics and major molecular agents that participate in setting the epigenome are reviewed herein. For each mechanism, the pharmacologic agents available for current use and the research underlying their approval are discussed. The potential impact of epigenetic pharmacology in pancreatic cancer is discussed in turn, and future directions of current research efforts are outlined.

Original languageEnglish (US)
Title of host publicationPancreatic Cancer
PublisherSpringer New York
Pages1551-1575
Number of pages25
ISBN (Electronic)9781493971930
ISBN (Print)9781493971916
DOIs
StatePublished - Apr 11 2018

Keywords

  • DNA methylation
  • DNA methyltransferase
  • DNAmethyltransferase inhibitor
  • Epigenetic pharmacology
  • Epigenetics
  • Histone deacetylase inhibitors
  • Histone modification
  • Pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Fingerprint Dive into the research topics of 'Epigenetic pharmacology'. Together they form a unique fingerprint.

Cite this